

2020 EFPIA Disclosure Report on Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organizations for Malta

Date of Publication: 07/04/2021

	Full Name <i>(Art. 1.01)</i>	HCPs: City of Principal Practice HCOs: city where registered <i>(Art. 3)</i>	Country of Principal Practice <i>(Schedule 1)</i>	Principal Practice Address <i>(Art. 3)</i>	Unique country identifier OPTIONAL <i>(Art. 3)</i>	Donations and Grants to HCOs <i>(Art. 3.01.1.a)</i>	Contribution to costs of Events <i>(Art. 3.01.1.b & Article 3.01.2.a)</i>			Fee for Service and consultancy <i>(Art. 3.01.1.c & Article 3.01.2.c)</i>		Transfers of Value re Research and Development as defined <i>(Art. 3.04)</i>	TOTAL OPTIONAL
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP /ORDM (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A		N/A
<i>OTHERS NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>													
HCPs	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>					N/A	N/A	356	0	0	0		356
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>					N/A	N/A	4	0	0	0		4
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>					N/A	N/A	100.0%	0.0%	0.0%	0.0%		100
<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>													
<i>OTHERS NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons</i>													
HCOs	Aggregate amount attributable to transfers of value to such Recipients - <i>Art. 3.02</i>					0.00	0.00	0.00	0.00	0.00	0.00		N/A
	Number of Recipients in aggregate disclosure - <i>Art. 3.02</i>					0	0	0	0	0	0		N/A
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - <i>Art. 3.02</i>					0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		N/A
AGGREGATE DISCLOSURE													
R&D	Transfers of Value re Research & Development as defined - <i>Article 3.04 and Schedule 1</i>											0.00	N/A